Related Experiment Video

Updated: Jun 21, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Targeting signal transducer and activator of transcription signaling pathway in leukemias

Mustafa Benekli1, Heinz Baumann, Meir Wetzler

  • 1Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|August 12, 2009
PubMed

Insights

Signal transducer and activator of transcription (STAT) proteins are key in cell growth. Aberrant STAT activation drives leukemia, highlighting STATs as therapeutic targets for novel cancer treatments.

Area of Science:

  • Molecular Biology
  • Cellular Signaling
  • Oncology

Background:

  • Signal transducer and activator of transcription (STAT) proteins are transcription factors activated by tyrosine phosphorylation.
  • Dysregulated STAT signaling is implicated in various leukemias and malignant cellular transformation.
  • Understanding STAT pathway dysregulation is crucial for developing targeted therapies.

Purpose of the Study:

  • To review the mechanisms of STAT protein activation.
  • To explore the role of STAT signaling in leukemogenesis.
  • To summarize recent advances in STAT-targeted drug discovery for leukemia.

Main Methods:

  • Literature review of STAT signaling pathways.
  • Analysis of studies on STAT activation in cancer.
  • Review of current therapeutic strategies targeting STAT proteins.

Main Results:

  • STAT proteins are activated by tyrosine phosphorylation via cytokines and growth factors.
  • Constitutive STAT activation is a hallmark of several leukemias.
  • STAT dysregulation plays a significant role in leukemogenesis.

Conclusions:

  • Targeting the STAT pathway offers promising therapeutic strategies for leukemia.
  • Further research into STAT mechanisms can lead to novel anti-leukemia drugs.
  • STAT proteins are critical targets for future cancer therapy development.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...